Bispecific antibody for ocular fundus(kexing)

N/A

Report date: 2026/02/13 20:01:31

Base Information

Drug NameBispecific antibody for ocular fundus(kexing)
Drug Alias NameGB10GB-10
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionVascular endothelial growth factor modulatorsAngiopoietin-2 modulators
TargetsVascular endothelial growth factorAngiopoietin-2
Therapy Area/IndicationsWet age-related macular degenerationMacular DegenerationEye Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShandong Kexing Bio-Products Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShenzhen Kexing Pharmaceutical Co Ltd
Inactive CompaniesShandong Kexing Bio-Products Co Ltd
Active IndicationsWet age-related macular degenerationMacular Degeneration
Inactive IndicationsEye Diseases

Other Information

ATC CodeN/A
Related LinksN/A